| NCT00309985 |
CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [CHAARTED] |
Phase 3 | 1.65 Miles |
|
| NCT00063882 |
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma |
Phase 3 | 1.79 Miles |
|
| NCT00772317 |
A Multicenter Clinical Study of the Sonablate® 500 (Sonablate) for the Treatment of Locally Recurrent Prostate Cancer With HIFU |
Phase 3 | 2.54 Miles |
|
| NCT00430183 |
Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer |
Phase 3 | 2.54 Miles |
|
| NCT00936390 |
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer |
Phase 3 | 2.86 Miles |
|
| NCT00988208 |
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or WITHOUT LENALIDOMIDE in Subjects With Castrate-Resistant Prostate Cancer |
Phase 3 | 2.86 Miles |
|
| NCT00567580 |
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy |
Phase 3 | 2.86 Miles |
|
| NCT00928434 |
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Loca |
Phase 3 | 3.27 Miles |
|
| NCT00278356 |
A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer |
Phase 1 | 6.14 Miles |
|
| NCT00227799 |
A Phase I Study of Image Guided Dose Escalation With Intensity Modulated Radiation Therapy (IMRT) to Histologically Confirmed Regions of Prostate Cancer |
Phase 1 | 6.14 Miles |
|
| NCT01090765 |
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) |
Phase 1/Phase 2 | 6.14 Miles |
|
| NCT00908258 |
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer |
Phase 1 | 6.14 Miles |
|
| NCT00942578 |
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer |
Phase 2 | 6.14 Miles |
|
| NCT00450619 |
A Randomized Phase 2.5 Study of (153)Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer |
Phase 2 | 6.14 Miles |
|
| NCT00450463 |
A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer |
Phase 2 | 6.14 Miles |
|
| NCT00079001 |
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone |
Phase 3 | 35.83 Miles |
|
| NCT00527124 |
A Randomized, Phase II Trial of AZD2171, Docetaxel, and Prednisone Compared to Docetaxel and Prednisone in Patients With Metastatic, Hormone Refractory Prostate Cancer |
Phase 2 | 35.83 Miles |
|
| NCT01083615 |
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Benefit of Adding Custirsen to Docetaxel Retreatment as Second-Line Therapy in Men With Castrate Resistance Prostate Cancer |
Phase 3 | 35.83 Miles |
|
| NCT00956904 |
Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy |
Phase 0 | 36 Miles |
|
| NCT00515112 |
A Randomized, Double Blind, Placebo-Controlled Phase II Study of Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer |
Phase 2 | 36.44 Miles |
|
| NCT00861614 |
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel |
Phase 3 | 36.63 Miles |
|
| NCT00670046 |
Randomized, Controlled Phase II Study of Valproic Acid in Patients With Non-metastatic Biochemical Progression of Prostate Cancer |
Phase 2 | 36.63 Miles |
|
| NCT00809991 |
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate |
Phase 2 | 36.63 Miles |
|
| NCT01118741 |
A Multi-institutional Translational Clinical Trial of Disulfiram in Men With Recurrent Prostate Cancer as Evident by a Rising PSA |
N/A | 36.63 Miles |
|
| NCT00959959 |
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer |
Phase 1/Phase 2 | 36.63 Miles |
|
| NCT01085422 |
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies |
Phase 1 | 36.63 Miles |
|
| NCT00734851 |
Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study |
Phase 2 | 38.37 Miles |
|
| NCT00776594 |
Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy |
Phase 2 | 38.44 Miles |
|
| NCT01084759 |
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer |
N/A | 38.44 Miles |
|
| NCT00551525 |
A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3DCRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy |
Phase 2 | 90.13 Miles |
|
| NCT01117935 |
Study of Hypofractionated Intensity Modulated External Beam Therapy for the Treatment of Patients With Adenocarcinoma of the Prostate |
N/A | 96.2 Miles |
|
| NCT01028885 |
A Prospective Study Implementing MRI Based Treatment Planning for Clinical Target Volume Definition and Immobilization in Post-Prostatectomy Radiation Treatment |
Phase 1 | 123.72 Miles |
|
| NCT00589420 |
A Phase II Study of Sorafenib in Combination With Docetaxel in Patients With Androgen-Independent Prostate Cancer |
Phase 2 | 123.72 Miles |
|
| NCT01045226 |
A Feasibility Trial of Proton Radiation Therapy Using Standard Fractionation for Low-Risk Adenocarcinoma of the Prostate |
N/A | 123.72 Miles |
|
| NCT00450411 |
A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy |
Phase 2 | 124.91 Miles |
|
| NCT00726596 |
NJ 1808: Autophagic Cell Death in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer |
Phase 2 | 129.74 Miles |
|
| NCT00377156 |
Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients With One to Three Cerebral Metastases |
Phase 3 | 143.61 Miles |
|
| NCT00887640 |
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer |
Phase 2 | 149.66 Miles |
|
| NCT00786682 |
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer |
Phase 2 | 157.85 Miles |
|
| NCT00132301 |
CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment (CAP) |
Phase 3 | 184.49 Miles |
|
| NCT00218205 |
A Phase II Trial of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Hormone Resistant Prostate Cancer (HRPC) |
Phase 2 | 197.89 Miles |
|
| NCT00215345 |
A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer |
Phase 2 | 197.89 Miles |
|
| NCT00698308 |
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone |
Phase 3 | 198.84 Miles |
|
| NCT00421902 |
Acupuncture Treatment for Hot Flashes in Men With Prostate Cancer, A Phase I/II Study |
Phase 1/Phase 2 | 203.98 Miles |
|
| NCT00241384 |
Low Dose Supplemental External Radiation With PD-103 Versus PD-103 Alone For Prostate Cancer |
Phase 3 | 206.18 Miles |
|
| NCT01163448 |
Phase I Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer |
Phase 1 | 208.76 Miles |
|
| NCT01140373 |
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) |
Phase 1 | 208.76 Miles |
|
| NCT00573833 |
A Pilot Study of High Dose Rate Brachytherapy as Definitive Management for Intermediate Risk Prostate Cancer |
N/A | 208.76 Miles |
|
| NCT01026623 |
Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 Plus mTOR Inhibitor Temsirolimus (CCI-779) in Metastatic Castration- Resistant Prostate Cancer (CRPC) |
Phase 1/Phase 2 | 208.76 Miles |
|
| NCT00604526 |
Pilot Study of High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy |
N/A | 208.76 Miles |
|
| NCT00195039 |
A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Androgen-Independent Prostate Cancer |
Phase 2 | 208.76 Miles |
|
| NCT00928850 |
A Randomized Trial of Modifications to Radical Prostatectomy: Feasibility Study |
N/A | 208.76 Miles |
|
| NCT00774436 |
A Phase II Study of Focal Cryoablation in Low-Risk Prostate Cancer |
Phase 2 | 208.76 Miles |
|
| NCT00859781 |
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy |
Phase 2 | 209.16 Miles |
|
| NCT00441571 |
A Phase 1 Study of Radiolabeled Monoclonal Antibody 7E11-C5.3(177Lu-meO-DOTA-7E11;CYT-500) in Patients With Progressive Androgen-Independent Prostate Cancer |
Phase 1 | 209.16 Miles |
|
| NCT00538668 |
Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer Using 177Lu-J591 Antibody: Dose Fractionation Regimen |
Phase 1 | 209.16 Miles |
|
| NCT00918385 |
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer |
Phase 2 | 224.97 Miles |
|
| NCT01163084 |
A Randomized Phase Ib/II Study of Preoperative GDC-0449 and Androgen Ablation Compared to Androgen Ablation Alone Followed by Radical Prostatectomy for Select Patients With Locally Advanced Adenocarcinoma of the Prostate |
Phase 1/Phase 2 | 224.97 Miles |
|
| NCT00941915 |
A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Continuous Real-time Evaluation of Prostate Motion and IMRT Plan Reoptimization Based on the Anatomy of the Day |
Phase 2 | 224.97 Miles |
|
| NCT00643617 |
Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry |
Phase 2 | 233.86 Miles |
|
| NCT00634582 |
Phase II Trial of Zemplar (19-nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer |
Phase 2 | 259.35 Miles |
|
| NCT00499408 |
Phase II Trial of Vitamin D and Soy Supplementation for Biochemically Recurrent Prostate Cancer Following Definitive Local Therapy |
Phase 2 | 259.35 Miles |
|
| NCT00536991 |
A Phase I/II Study of Oral Calcitriol in Combination With Ketoconazole in Androgen Independent Prostate Cancer |
Phase 1/Phase 2 | 289.9 Miles |
|
| NCT00887432 |
Randomized Placebo-Controlled, Double-Blind Study Of Cholecalciferol Replacement in Patients on Expectant Management for Localized Prostate Cancer |
N/A | 289.9 Miles |
|
| NCT00736645 |
A Randomized, Double Blind, Placebo Controlled Clinical Trial of L-SeMet Supplementation and Finasteride Treatment of Patients With Prostate Cancer Prior to Robotic Prostatectomy/Brachytherapy |
Phase 2 | 289.9 Miles |
|
| NCT00924469 |
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer |
Phase 2 | 289.9 Miles |
|
| NCT00619515 |
Prospective Evaluation of Cyberknife Stereotactic Radiosurgery for Low and Low/Intermediate Risk Prostate Cancer |
N/A | 293.31 Miles |
|
| NCT01083368 |
Phase I-II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Avastin in Patients With Chemotherapy Refractory Castrate Resistant Prostate Cancer (CRPC) |
Phase 1/Phase 2 | 294.35 Miles |
|
| NCT00438464 |
A Randomized Controlled Trial Evaluating the Tissue Effects of Preoperative Finasteride Versus Placebo for Patients With Clinically Organ-Confined Prostate Cancer |
Phase 2 | 301.88 Miles |
|
| NCT01009736 |
Biomarkers of Prostate and Cardiovascular Health of Men Undergoing Prostatectomy Consuming Different Amounts of Soy-Tomato Juice |
Phase 1/Phase 2 | 325.95 Miles |
|
| NCT00757692 |
A Phase II Randomised Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer. |
Phase 2 | 331.58 Miles |
|
| NCT00486642 |
A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Hormone Refractory Prostate Cancer |
Phase 2 | 331.58 Miles |
|
| NCT00304759 |
A Randomized Trial of a Shorter Radiation Fractionation Schedule for the Treatment of Localized Prostate Cancer |
Phase 3 | 331.58 Miles |
|
| NCT00741364 |
Randomized Trial of the Effects of Vitamin D on Prostate Cancer-Associated Lesions and on Vitamin D Metabolites in Prostate |
Phase 2 | 348.78 Miles |
|
| NCT00002651 |
Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III |
Phase 3 | 348.79 Miles |
|
| NCT00789607 |
Fiducial Localization and Individualized Radiotherapy in Prostate Cancer (FLIP) |
Phase 2 | 348.79 Miles |
|
| NCT01075308 |
A Phase II Study of SB939 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer |
Phase 2 | 348.79 Miles |
|
| NCT00480090 |
A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer |
Phase 2 | 348.79 Miles |
|
| NCT00913939 |
MRI-Guided HDR Brachytherapy for Prostate Cancer |
N/A | 348.79 Miles |
|
| NCT00881725 |
A Phase II, Open Label Assessment of Neoadjuvant Intervention With Metformin Against Tumour Expression of Signaling |
Phase 2 | 348.79 Miles |
|
| NCT00791115 |
Salvage Prostatectomy After Radiotherapy: Whole-Mount Histopathological Validation for Tumor-Targeted Salvage HDR Brachytherapy |
N/A | 348.79 Miles |
|
| NCT01094665 |
Phase 1 Study of MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer |
Phase 1 | 348.79 Miles |
|
| NCT01146340 |
Phase I/II Study of Dose-Escalated Hypofractionated Radiotherapy for Low- and Intermediate-Risk Prostate Cancer |
Phase 1/Phase 2 | 352.61 Miles |
|
| NCT00318240 |
Feasibility Study for Locally Recurrent Prostate Cancer Treatment Following Radiation Failure With High Intensity Focused Ultrasound (HIFU) |
N/A | 355.08 Miles |
|
| NCT00664196 |
Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning |
Phase 1 | 358.7 Miles |
|
| NCT00828308 |
BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study |
Phase 2 | 360.64 Miles |
|
| NCT00770822 |
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU |
N/A | 368.09 Miles |
|
| NCT00103376 |
VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer |
Phase 2 | 382.57 Miles |
|
| NCT00805701 |
Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incisio |
Phase 4 | 390.36 Miles |
|
| NCT00953576 |
A Phase I/II Trial of Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Castration Resistant Prostate Cancer With Pre- and Post-therapy Tumor Biopsies |
Phase 1/Phase 2 | 392.57 Miles |
|
| NCT00116142 |
Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial |
Phase 3 | 392.57 Miles |
|
| NCT00458549 |
Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids |
N/A | 392.57 Miles |
|
| NCT00888654 |
Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy |
Phase 2 | 392.84 Miles |
|
| NCT00478413 |
Phase II Trial of Avastin (Bevacizumab) in PSA Relapse Androgen Independent Prostate Cancer |
Phase 2 | 392.84 Miles |
|
| NCT01051570 |
Phase II Trial of Carboplatin and RAD001 in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy. |
Phase 2 | 392.84 Miles |
|
| NCT01046916 |
A Phase 2 Multicenter Open-label Study Evaluating the Safety and Efficacy of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer (CRPC) and a Rising Prostate-specific Antigen (PSA) |
Phase 2 | 418.53 Miles |
|
| NCT00480857 |
Salvage Radiation Therapy and Docetaxel (Taxotere) for Biochemical Failure After Radical Prostatectomy |
Phase 2 | 418.53 Miles |
|
| NCT01045109 |
Vitamin D and Prostate Cancer |
Phase 2 | 452.78 Miles |
|
| NCT00099086 |
Phase I Trial of Concurrent Taxotere With Radiation Therapy and Hormonal Therapy For Clinically Localized High Risk Prostate Cancer |
Phase 1 | 452.78 Miles |
|
| NCT00953225 |
Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer |
Phase 2 | 452.78 Miles |
|
| NCT00326638 |
Randomized Phase III Trial of 3D Conformal Radiotherapy Versus Helical Tomotherapy IMRT in High-Risk Prostate Cancer |
Phase 3 | 453.68 Miles |
|
| NCT00223145 |
Randomized, Multicentre, Phase III Study in Patients With Intermediate-Risk T1 T2 Prostate Adenocarcinomas, to Verify the Role of Six Months of Total Androgen Blockade for Two Dosage Levels of Prostate Radiation Therapy (70 Gy and 76 Gy) Versus Prostate R |
Phase 3 | 523.82 Miles |
|
| NCT00223171 |
Randomized, Multicentre, Phase III Study: Assessment of the Duration of Androgen Blockade Combined With Pelvic Irradiation in High-Risk Prostate Cancers |
Phase 3 | 523.82 Miles |
|
| NCT00288444 |
Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies |
Phase 1 | 539.08 Miles |
|
| NCT00313456 |
A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel |
Phase 1 | 563.36 Miles |
|
| NCT00668642 |
Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate Cancer |
Phase 2 | 587.39 Miles |
|
| NCT00765479 |
Randomized Placebo-Controlled Adjuvant Study of Prevention of Prostate Cancer Recurrence After Radical Prostatectomy by Soy Protein Isolate |
Phase 2/Phase 3 | 593.78 Miles |
|
| NCT00414388 |
Phase I/II Study to Evaluate the Ability of Sorafenib in Overcoming Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer (AIPC) |
Phase 1/Phase 2 | 599.01 Miles |
|
| NCT00424385 |
Phase I Study Investigating the Safety and Feasibility of Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-Independent Chemotherapy-Failure Prostate Cancer. |
Phase 1 | 602.9 Miles |
|
| NCT00654186 |
A Phase II Study Evaluating the Toxicity and Efficacy of Single Agent Lenalidomide (Revlimid®) in Chemotherapy-Naïve Androgen-Independent Prostate Cancer Patients |
Phase 2 | 602.9 Miles |
|
| NCT00919035 |
Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients |
Phase 2 | 602.9 Miles |
|
| NCT00969111 |
Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy |
Phase 2 | 645.3 Miles |
|
| NCT00693238 |
A Phase II Study of Hypofractionated Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate |
Phase 2 | 645.3 Miles |
|
| NCT01040624 |
A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma |
Phase 2 | 645.3 Miles |
|
| NCT00945477 |
A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist. |
Phase 2 | 677.52 Miles |
|
| NCT01119118 |
Pharmacodynamic Response Assessment With PET/MRI Imaging in Patients With Metastatic Prostate CAncer to Bone Treated With ZD4054 |
Phase 2 | 702.62 Miles |
|
| NCT00849121 |
A Pilot Randomized Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer |
Phase 2 | 702.62 Miles |
|
| NCT00214097 |
Phase I/II Trial Examining Dose-per-Fraction Escalation Using Intensity Modulated Radiation Therapy in the Treatment of Prostate Cancer |
Phase 1/Phase 2 | 702.62 Miles |
|
| NCT00583752 |
Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy |
Phase 2 | 784.27 Miles |
|
| NCT00583024 |
Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer |
Phase 2 | 784.27 Miles |
|
| NCT01036321 |
Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness and Mechanism of Action Between African American and Caucasian Men |
Phase 2 | 810.95 Miles |
|
| NCT00694551 |
Pilot Immunotherapy Study of Combination PSMA and TARP Peptide With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment |
N/A | 810.95 Miles |
|
| NCT00788307 |
Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine |
Phase 1 | 869.17 Miles |
|
| NCT00937768 |
Phase II Trial of Temporary Androgen Deprivation Therapy in High Risk Prostate Cancer Following Radical Prostatectomy |
Phase 2 | 869.17 Miles |
|
| NCT01093183 |
A Phase I/II Clinical Trial of Lenalidomide in Combination With Oral Cyclophosphamide in Patients With Previously Treated Hormone Refractory Prostate Cancer |
Phase 1/Phase 2 | 1008.82 Miles |
|
| NCT00547339 |
A Phase I and II Study of Stereotactic Body Radiation Therapy (SBRT) for Low and Intermediate Risk Prostate Cancer (SBRT Prostate) |
Phase 1/Phase 2 | 1179.15 Miles |
|
| NCT01079793 |
A Phase I/II Study of Adjuvant Prostate Irradiation and Ixabepilone For High Risk Prostate Cancer Post-Prostatectomy |
Phase 1/Phase 2 | 1179.15 Miles |
|
| NCT01088529 |
A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone |
Phase 2 | 1219.64 Miles |
|
| NCT00616291 |
Immunotherapy of Patients With Androgen-Independent Prostate Carcinoma Using NY-ESO-1/LAGE1 Peptide Vaccine (SPORE #: 11-01-30-14) |
Phase 1 | 1219.64 Miles |
|
| NCT00872157 |
A Limited, First-in-Man, Phase IB Evaluation of BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With High-Volume Osseous Metastases and no Standard Treatment Options |
Phase 1 | 1219.64 Miles |
|
| NCT00877682 |
Regional Cryoablation for Localized Adenocarcinoma of the Prostate |
N/A | 1219.64 Miles |
|
| NCT00831792 |
An Observational Study of Continuous TKI258, in Castration-Resistant Prostate Cancer Patients Evaluating Markers of FGF Signaling in Bone Marrow Plasma. |
Phase 2 | 1219.64 Miles |
|
| NCT00525720 |
Transperineal Interstitial Permanent Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma |
Phase 2 | 1219.64 Miles |
|
| NCT00933426 |
A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases |
Phase 1/Phase 2 | 1219.64 Miles |
|
| NCT00985738 |
A Randomized Placebo-Controlled Double-Blind Clinical Trial to Assess the Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer |
Phase 3 | 1477.73 Miles |
|
| NCT00809458 |
A Phase III Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer Prior to Prostatectomy or Brachytherapy |
Phase 3 | 1643.47 Miles |
|
| NCT00752739 |
Phase II Chemoprevention Trial of Selenium and Prostate Cancer (Watchful Waiting With Selenium Trial) |
Phase 2 | 1944.42 Miles |
|
| NCT00822510 |
|
Phase 1 | 1945.48 Miles |
|
| NCT01050842 |
Pilot Trial to Evaluate the Safety and Efficacy of the Administration of Bicalutamide (Casodex TM) Per Day in Combination With Raloxifene (Evista TM) Per Day in Patients With Hormone Refractory Prostate Cancer |
N/A | 1956.26 Miles |
|
| NCT00127816 |
Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy |
N/A | 1981.39 Miles |
|
| NCT00126802 |
The Role of Tomotherapy (Dynamic IMRT and Megavoltage CT Scanning) in Hypofractionated/Dose Escalated Conformal Radiation Treatment Using Magnetic Resonance Spectroscopy (MRS) Scans to Predict and Document the Pattern of Local Failure for High Risk Prosta |
Phase 1/Phase 2 | 1981.39 Miles |
|
| NCT00831623 |
Phase I-II Trial of Hypofractionated Conformal Proton Beam Radiation Therapy for Favorable-risk Prostate Cancer |
Phase 1/Phase 2 | 2237.13 Miles |
|
| NCT00969202 |
Phase 1 Study of Stereotactic Hypofractionated Radiosurgery of Low Grade Prostate Cancer/Early Stage |
Phase 1 | 2248.05 Miles |
|
| NCT00851916 |
VIRTUAL HDR CYBERKNIFE RADIOSURGERY FOR LOCALLY RECURRENT PROSTATIC CARCINOMA: A PHASE II STUDY |
Phase 2 | 2261.98 Miles |
|
| NCT00779168 |
A Phase Ib of Mushroom Powder in Biochemically Recurrent, Hormone Naive Prostate Cancer |
Phase 1 | 2272.79 Miles |
|
| NCT00879619 |
A Pilot Phase II Study to Determine the Effects of Taxotere Plus Sunitinib on Newly Diagnosed, Hormone Refractory, Symptomatic and Asymptomatic, Metastatic Prostate Cancer Who Are Chemotherapy-naïve. |
Phase 2 | 2277.37 Miles |
|
| NCT00669656 |
A Phase II Trial of a Combination Herbal Therapy for Men With Biochemical Recurrence of Prostate Cancer After Initial Local Therapy |
Phase 2 | 2288.63 Miles |
|
| NCT00669162 |
A Phase I/II Trial of Adjuvant 3-D Conformal Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3N0M0 Prostate Cancer |
Phase 1/Phase 2 | 2288.63 Miles |
|
| NCT00574769 |
Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer |
Phase 1/Phase 2 | 2288.63 Miles |
|
| NCT00685516 |
A Phase II Randomized, Open-Label, Three-Arm Study of Green Tea, Black Tea and a Water Control in Men Scheduled for Prostatectomy |
Phase 2 | 2300.53 Miles |
|
| NCT01059513 |
Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer |
Phase 2 | 2300.53 Miles |
|
| NCT00769795 |
Phase II Study of Neoadjuvant IMC-A12 Combined With Androgen Deprivation Prior to Prostatectomy |
Phase 2 | 2316.27 Miles |
|
| NCT00486499 |
|
Phase 3 | 2317.15 Miles |
|
| NCT00223665 |
A Prospective Study of Intermittent Androgen Suppression in Men With Localized Prostate Cancer Who Have Biochemical Relapse After Radiation Therapy or Radical Prostatectomy |
Phase 2 | 2318.25 Miles |
|
| NCT01023061 |
Phase II Trial of Radiation With Androgen Deprivation (RAD): Abiraterone Acetate, Prednisone and LHRH Agonist Prior to and Concurrent With Radiation Therapy |
Phase 2 | 2318.25 Miles |
|
| NCT00753220 |
A Phase I/IIa Trial of Combined Cryotherapy and Intra-tumoral Immunotherapy With Autologous Immature Dendritic Cells (VDC2008) in Chemo-naïve Men With Prostatic Adenocarcinoma and Limited Metastases to Lymph Nodes and/or Bone |
Phase 1/Phase 2 | 2336.87 Miles |
|
| NCT00488982 |
A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy With Maintenance GM-CSF in Patients With Previously Untreated Hormone Refractory Prostate Cancer |
Phase 2 | 2344.32 Miles |
|
| NCT00175396 |
A Randomized Phase III Study Comparing Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by High Dose 3-D Conformal Boost Versus Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by 125-Iodine Brachytherapy Implant Boos |
Phase 3 | 2351.82 Miles |
|
| NCT01100866 |
Randomized Controlled Trial of POMELLA™ Extract in Prostate Cancer Patients Scheduled for Surgery |
N/A | 2352.07 Miles |
|
| NCT00175383 |
A Randomized Trial of Short Versus Long Acting LHRH Agonist Preparation Prior to Transperineal Implantation of the Prostate |
Phase 3 | 2362.03 Miles |
|
| NCT00814788 |
Randomized Phase II Trial of Bicalutamide +/- RAD001 in Patients With Hormone-Independent Prostatic Adenocarcinoma (HIPC) After the First-Line Androgen Deprivation Therapy |
Phase 2 | 2365.89 Miles |
|
| NCT00284752 |
Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer |
Phase 2 | 2415.32 Miles |
|
| NCT01020305 |
Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients With Castration-resistant Prostate Cancer |
Phase 1/Phase 2 | 2424.61 Miles |
|
| NCT01036594 |
An Endocrinologically and Pharmacologically Directed Trial of Ketoconazole and Corticosteroids in Castration Resistant Prostate Cancer |
Phase 2 | 2431.67 Miles |
|
| NCT00305669 |
A Pilot Study of Two Dose Schedules of Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) as Neo-Adjuvant Therapy in Patients With Localized Prostate Cancer |
N/A | 2431.67 Miles |
|
| NCT01084655 |
An Open-label Phase 1/2 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer |
Phase 1/Phase 2 | 3353.78 Miles |
|
